[3H]-methyllycaconitine | 21019-30-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [3H]-methyllycaconitine
• 英文别名: α-bungarotoxin；methyllycaconitine；methyllycaconit；[3H]-MLA；[(1S,2R,3R,4S,5R,6S,8R,9S,13S,16S,17R,18S)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.12,5.01,10.03,8.013,17]nonadecan-13-yl]methyl 2-[(3S)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate
• CAS: 21019-30-7
• 化学式: C₃₇H₅₀N₂O₁₀
• 分子量: 682.811
• InChiKey: XLTANAWLDBYGFU-UNYSBPQLSA-N

物化性质

• 熔点：
  128 °C
• 沸点：
  694.34°C (rough estimate)
• 密度：
  1.1852 (rough estimate)
• 溶解度：
  在水中的溶解度42 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  49
• 可旋转键数：
  10
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  144
• 氢给体数：
  2
• 氢受体数：
  11

制备方法与用途

类别：有毒物品

毒性分级：剧毒

急性毒性：

• 静脉注射 - 小鼠 LD50：3.0 毫克/公斤

可燃性危险特性：

• 明火、受热、与氧化剂接触可燃；
• 燃烧时会产生氮氧化物烟雾

储运特性：

• 库房需保持通风、低温和干燥环境
• 装卸时应轻拿轻放，避免与其他食品原料混存

灭火方法：

• 使用雾状水或泡沫进行灭火

反应信息

• 作为反应物：
  描述：

  [3H]-methyllycaconitine 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 13.0h， 以77%的产率得到lycoctonine
  参考文献：
  名称：

  Nudicauline and Elatine as Potent Norditerpenoid Ligands at Rat Neuronal α-Bungarotoxin Binding Sites:  Importance of the 2-(Methylsuccinimido)benzoyl Moiety for Neuronal Nicotinic Acetylcholine Receptor Binding

  摘要：

  Methyllycaconitine (MLA, 1) is a novel, potent probe for mammalian and insect nicotinic acetylcholine receptors (nAChR) and displays remarkable selectivity toward neuronal [I-125]- alpha-bungarotoxin (alpha BgTX) binding sites that correspond to alpha 7-type nAChR in mammalian brain. We have shown that, among a number of selected norditerpenoid alkaloids, elatine (2) and nudicauline (3) are equipotent with, or better than, MLA (1) in binding to brain [I-125]-alpha BgTX binding sites, with IC50 values of 6.1, 1.7, and 7.6 nM, respectively. The 2-((S)-methylsuccinimido)benzoyl moiety of these Ligands is crucial for high-affinity binding, whereas structural modifications to the norditerpenoid core of the ligand can be tolerated without loss of activity or selectivity. In addition to MLA (1), elatine (2), and nudicauline (3), we have examined lycoctonine (4), inuline (6), lappaconitine (7), N-desacetyllappaconitine (8), delsoline (10), delcorine (11), deltaline (12), condelphine (13), and karacoline (14). This study therefore extends the range of norditerpenoids, other than MLA, which can be used to probe this important class of nAChR. All 12 alkaloids were assessed for activity at [H-3]nicotine binding sites which are considered to represent alpha 4 beta 2 nAChR. Furthermore, the H-1 and C-13 NMR spectroscopic data of MLA and elatine have been critically compared.

  DOI：

  10.1021/jm9604991

文献信息

• Azabicyclic compounds for the treatment of disease
  申请人：——

  公开号：US20030232853A1

  公开（公告）日：2003-12-18

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中Azabicyclo是 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对已知涉及α7的药物具有用处。
• Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
  申请人：——

  公开号：US20030105089A1

  公开（公告）日：2003-06-05

  The invention provides compounds of Formula I: 1 which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which &agr;7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.

  这项发明提供了Formula I的化合物： 1 这些化合物可以是药用可接受的盐或组合物的形式，对治疗涉及α7尼古丁型乙酰胆碱受体(nAChRs)的疾病或症状是有用的。
• USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
  申请人：PAPKE Roger L.

  公开号：US20100179186A1

  公开（公告）日：2010-07-15

  This application provides a method for the use of select quaternary ammonium antagonists to alpha-7 nAChR for the treatment of cancer and HIV and AIDS.

  该应用程序提供了一种使用选择性四价铵拮抗剂对α-7 nAChR进行治疗癌症、HIV和艾滋病的方法。
• Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
  申请人：——

  公开号：US20030073707A1

  公开（公告）日：2003-04-17

  The invention provides compounds of Formula I: 1 wherein W 0 is a bicyclic moiety and is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful to treat diseases or conditions in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中W0是一个双环基团，是 这些化合物可以是药物盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7的疾病或症状有用。
• Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
  申请人：——

  公开号：US20030236264A1

  公开（公告）日：2003-12-25

  The invention provides compounds of Formula I: 1 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which &agr;7 is known to be involved.

  这项发明提供了I式化合物： 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对于治疗已知涉及α7的疾病或病症的药物非常有用。